Regulation & Approvals
Sanofi's Infilbray Becomes First FDA-Approved Medicine for Type 3 Gaucher Neurological Symptoms
By News Desk ·
Key takeaways
- The FDA approved Infilbray (venglustat) for neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15 kg.
- The LEAP2MONO phase 3 study showed Infilbray was statistically superior to imiglucerase on a global test of neurological endpoints, with p=0.0137.
- Sanofi plans additional global regulatory submissions for Infilbray in Type 3 Gaucher disease in 2026 and 2027.
Sanofi won U.S. Food and Drug Administration approval for Infilbray (venglustat) on November 18, 2026, making it the first medicine cleared to treat neurological manifestations of Type 3 Gaucher disease in adults and pediatric patients weighing at least 15 kg. GlobeNewswire published the announcement. Sanofi is a Paris-based biopharmaceutical company that develops prescription medicines, vaccines and consumer healthcare products across immunology, neurology, oncology, rare diseases and vaccines.
How Infilbray Targets Type 3 Gaucher Disease
Infilbray is a once-daily oral glucosylceramide synthase inhibitor designed to act across the blood-brain barrier, where it targets the abnormal accumulation of glycosphingolipids that drives neuroinflammation in Type 3 Gaucher disease. The condition is the chronic neuronopathic form of Gaucher disease, causing cognitive deficits and difficulty with coordination and balance alongside systemic symptoms such as liver and spleen enlargement, anemia, thrombocytopenia and bone disease.
The approval rests on the LEAP2MONO phase 3 study, a double-blinded, double-dummy, active-comparator, two-arm trial that randomized 43 patients aged 12 and older to Infilbray or intravenous imiglucerase every two weeks. A global test of multiple neurological endpoints showed statistically significant superiority for Infilbray over the enzyme replacement therapy, with p=0.0137. The endpoints measured change from baseline to Week 52 on the 4-item SARA score and the RBANS total scale index score.
"Patients living with Type 3 Gaucher disease face a long and difficult road to accurate diagnosis, often going years without answers while neurological manifestations progress," said Aviva Rosenberg, CEO and Co-Founder of the Gaucher Community Alliance. "Today's Infilbray approval marks a long-awaited advancement for those experiencing devastating neurological symptoms of Type 3 Gaucher disease."
Infilbray carries Warnings and Precautions for Suicidal Ideation and Behavior, Lens Opacification in Pediatric Patients, and Embryofoetal Toxicity. In the primary analysis period, adverse reactions among patients receiving Infilbray (n=21) versus imiglucerase (n=22) included diarrhea at 14% versus 0%, splenomegaly at 14% versus 0%, nausea at 14% versus 5%, depression at 10% versus 0%, gastroenteritis at 10% versus 0% and vomiting at 10% versus 5%.
Sanofi's Record on Rare Disease Approvals
According to akta.pro company records, Sanofi operates in more than 100 countries and employs more than 83,000 people. The same records list total funding of $10.1 billion, with the most recent round dated September 8, 2026.
Earlier Steps Toward the Infilbray Approval
On November 18, 2026, Yahoo reported that the FDA approved Sanofi's oral drug venglustat, making it the first treatment for a rare genetic condition affecting the brain and nervous system. Two days earlier, Newswire reported that Sanofi and the pan-Canadian Pharmaceutical Alliance signed a Letter of Intent for Sarclisa (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone for first-line treatment of newly diagnosed multiple myeloma patients ineligible for transplant. On November 17, 2026, Investing.com reported that Sanofi outlined a sharper vaccines strategy at the Jefferies Global Healthcare Conference, naming vaccines a core growth area alongside immunology and rare diseases.
What Comes Next for Infilbray
Infilbray is under regulatory review for Type 3 Gaucher disease in the EU, Japan and other jurisdictions, and Sanofi said it will pursue additional global regulatory submissions in 2026 and 2027. The open-label phase of LEAP2MONO is ongoing, and Sanofi said results from that phase will be presented when available.